Science· 2004Q1
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- 9,461citations
- Q1SCImago
- 2004year
Short summary
Somatic mutations in the EGFR gene predict sensitivity to the EGFR inhibitor gefitinib in non-small cell lung cancer (NSCLC).
AI-generated from the title and abstract; the full text is not read.
Key points
- EGFR somatic mutations found in 15/58 Japanese and 1/61 US NSCLC tumors.
- EGFR mutations present in gefitinib-responding NSCLC patients and hypersensitive cell lines.
- EGFR mutations absent in gefitinib-insensitive tumors and cell lines.
- EGFR mutations may predict sensitivity to gefitinib therapy.
AI-generated from the title and abstract; the full text is not read.
Abstract
Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.
The authors' abstract, as published at the source. Science, 2004 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine